Related Experiment Videos
Trabecular and cortical bone loss in systemic lupus erythematosus
F A Houssiau1, C Lefebvre, G Depresseux
1Department of Rheumatology, St-Luc University Hospital, Louvain University in Brussels, Belgium.
British Journal of Rheumatology
|March 1, 1996
Summary
Systemic lupus erythematosus (SLE) patients exhibit reduced bone mineral density (BMD) at multiple sites. Glucocorticoid treatment further lowers lumbar spine BMD, indicating increased fracture risk in SLE patients.
Area of Science:
- Rheumatology
- Endocrinology
- Orthopedics
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
- Bone mineral density (BMD) loss is a potential complication in SLE patients.
- Glucocorticoids are commonly used to manage SLE but can negatively impact bone health.
Purpose of the Study:
- To assess bone mineral density (BMD) in premenopausal women with SLE.
- To investigate the impact of glucocorticoid treatment on BMD in SLE patients.
- To determine if SLE disease activity contributes to bone loss independently of medication.
Main Methods:
- Dual-energy X-ray absorptiometry (DXA) was used to measure BMD.
- 47 premenopausal female SLE patients and healthy controls were included.
- BMD was assessed at the lumbar spine, hip (total and sub-regions), and total body.
Main Results:
- SLE patients showed significantly lower BMD at all measured trabecular and cortical sites compared to controls.
- Patients with a history of glucocorticoid treatment had lower lumbar spine BMD than those never treated.
- Bone loss correlated with cumulative oral glucocorticoid intake.
- Even without glucocorticoid treatment, SLE patients had lower hip BMD, suggesting disease-related bone loss.
Conclusions:
- Systemic lupus erythematosus (SLE) is associated with widespread bone mineral density (BMD) loss.
- Glucocorticoid therapy exacerbates bone loss, particularly at the lumbar spine.
- SLE patients face an elevated risk of fractures due to compromised bone health.